Jun 13 |
Gritstone bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
May 11 |
Gritstone bio First Quarter 2024 Earnings: Misses Expectations
|
May 10 |
Gritstone bio Inc. (GRTS) Q1 2024 Earnings Call Transcript
|
May 9 |
Gritstone bio GAAP EPS of -$0.34 misses by $0.02, revenue of $1.74M misses by $1.11M
|
May 9 |
Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates
|
May 8 |
Gritstone bio Q1 2024 Earnings Preview
|
May 2 |
Gritstone bio to Report First Quarter 2024 Financial Results and Provide Corporate Updates on May 9, 2024
|
Apr 30 |
Gritstone bio Highlights the Durability and Potential Broad Utility of its Self-amplifying mRNA (samRNA) COVID-19 Vaccine at ESCMID Global 2024
|
Apr 15 |
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
|
Apr 8 |
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024
|